FARALLON CAPITAL MANAGEMENT LLC
13F Reported Value
ⓘ$21.7B
incl. option notional
Equity Holdings
ⓘ$17.1B
Option Notional
ⓘ$4.6B
$4.6B puts / $28.4M calls
Holdings
89
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
FARALLON CAPITAL MANAGEMENT LLC disclosed 89 positions worth $21.7B in its Form 13F-HR for Q2 2026 — $17.1B in common stock plus $4.6B of put/call option positions (reported at underlying notional value, not premium at risk), led by $SPY (SPDR S&P 500 ETF TRUST) puts, followed by $RVMD and $EA. During the quarter the fund opened 21 new positions and exited 105 — including a new stake in $EA. The portfolio is most concentrated in Healthcare (66.5% of disclosed assets). All figures are sourced directly from FARALLON CAPITAL MANAGEMENT LLC’s Form 13F-HR filing with the SEC under CIK 909661.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$4.5B6,000,000 sh - —
Quality
$2.5B13,550,796 sh - 62.9#671
Quality
$1.6B7,919,500 sh - 36.9
Quality
$800.1M10,743,063 sh - 59.4
Quality
$778.2M6,348,906 sh - 76.2
Quality
$732.8M13,468,010 sh - 78.3
Quality
$666.9M8,365,038 sh - 68.7
Quality
$627.5M2,632,994 sh - 61.1
Quality
$619.4M5,583,479 sh - 53.5
Quality
$602.2M2,218,366 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 SPDR S&P 500 ETF TRUST$SPYPUT | — | $4.5B | 6,000,000 |
 Revolution Medicines, Inc.$RVMD | — | $2.5B | 13,550,796 |
 ELECTRONIC ARTS INC.$EA | 62.9#671 | $1.6B | 7,919,500 |
 BridgeBio Pharma, Inc.$BBIO | 36.9 | $800.1M | 10,743,063 |
 Protagonist Therapeutics, Inc$PTGX | 59.4 | $778.2M | 6,348,906 |
 EXELIXIS, INC.$EXEL | 76.2 | $732.8M | 13,468,010 |
 Liquidia Corp$LQDA | 78.3 | $666.9M | 8,365,038 |
 AMAZON COM INC$AMZN | 68.7 | $627.5M | 2,632,994 |
 Lantheus Holdings, Inc.$LNTH | 61.1 | $619.4M | 5,583,479 |
 Natera, Inc.$NTRA | 53.5 | $602.2M | 2,218,366 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of FARALLON CAPITAL MANAGEMENT LLC's 89 positions.
Showing top 10 of 89 holdings.
Sector Allocation
Healthcare
$11.4B
Technology
$3.6B
Financials
$929.5M
Consumer Discretionary
$833.9M
Industrials
$251.3M
Other
$49.2M
Materials
$44.0M
Energy
$2.2M
Full Holdings — FARALLON CAPITAL MANAGEMENT LLC (Q2 2026)
All 89 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SPYPUT | SPDR S&P 500 ETF TRUST | $4.5B | — | +161% | — |
| 2 | $RVMD | Revolution Medicines, Inc. | $2.5B | 14.9% | -0% | — |
| 3 | $EA | ELECTRONIC ARTS INC. | $1.6B | 9.5% | NEW | 62.9 |
| 4 | $BBIO | BridgeBio Pharma, Inc. | $800.1M | 4.7% | +15% | 36.9 |
| 5 | $PTGX | Protagonist Therapeutics, Inc | $778.2M | 4.6% | +0% | 59.4 |
| 6 | $EXEL | EXELIXIS, INC. | $732.8M | 4.3% | +3% | 76.2 |
| 7 | $LQDA | Liquidia Corp | $666.9M | 3.9% | -3% | 78.3 |
| 8 | $AMZN | AMAZON COM INC | $627.5M | 3.7% | -38% | 68.7 |
| 9 | $LNTH | Lantheus Holdings, Inc. | $619.4M | 3.6% | +0% | 61.1 |
| 10 | $NTRA | Natera, Inc. | $602.2M | 3.5% | -31% | 53.5 |
| 11 |  $UNH | UNITEDHEALTH GROUP INC | $528.1M | 3.1% | -30% | 62.7 |
| 12 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $526.0M | 3.1% | +19% | 65.1 |
| 13 |  $ROIV | Roivant Sciences Ltd. | $506.4M | 3.0% | +48% | — |
| 14 |  $AON | Aon plc | $458.6M | 2.7% | -45% | — |
| 15 |  $BSX | BOSTON SCIENTIFIC CORP | $449.0M | 2.6% | +41% | 77.5 |
| 16 |  $AVGO | Broadcom Inc. | $435.1M | 2.5% | -35% | 84.5 |
| 17 |  $MSFT | MICROSOFT CORP | $415.1M | 2.4% | -53% | 79.8 |
| 18 |  $TNGX | Tango Therapeutics, Inc. | $383.8M | 2.3% | +35% | 17.6 |
| 19 |  $KKR | KKR & Co. Inc. | $378.0M | 2.2% | -12% | 54.3 |
| 20 |  $SNPS | SYNOPSYS INC | $370.1M | 2.2% | -32% | 67.9 |
| 21 |  $BEAM | Beam Therapeutics Inc. | $351.3M | 2.1% | +1% | 34.2 |
| 22 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $336.4M | 2.0% | +8% | 25.5 |
| 23 |  $GRAL | GRAIL, Inc. | $284.1M | 1.7% | +28% | 31.6 |
| 24 |  $WAB | WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORP | $241.2M | 1.4% | -44% | 66.3 |
| 25 |  $IMVT | Immunovant, Inc. | $223.7M | 1.3% | +275% | — |
| 26 |  $TWST | Twist Bioscience Corp | $219.8M | 1.3% | +50% | 33.9 |
| 27 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $219.6M | 1.3% | +4% | 26.9 |
| 28 |  $ARMK | Aramark | $206.3M | 1.2% | -41% | 47.1 |
| 29 |  $BIDU | Baidu, Inc. | $137.6M | 0.8% | +171% | 27 |
| 30 |  $NVO | NOVO NORDISK A S | $125.6M | 0.7% | +235% | — |
| 31 |  $ACHC | Acadia Healthcare Company, Inc. | $124.6M | 0.7% | +143% | 36.7 |
| 32 |  $BTSG | BrightSpring Health Services, Inc. | $120.8M | 0.7% | +7% | 63.3 |
| 33 |  $AZN | ASTRAZENECA PLC | $108.8M | 0.6% | +153% | — |
| 34 |  $JNJ | JOHNSON & JOHNSON | $103.6M | 0.6% | +176% | 69 |
| 35 | — | ISHARES TR - ISHARES SEMICDTR | $83.3M | — | NEW | — |
| 36 |  $MSTR | Strategy Inc | $75.4M | 0.4% | +122% | 17.9 |
| 37 |  $PBLS | Parabilis Medicines, Inc. | $64.8M | 0.4% | NEW | — |
| 38 |  $NVS | NOVARTIS AG | $56.9M | 0.3% | NEW | — |
| 39 |  $GH | Guardant Health, Inc. | $48.3M | 0.3% | +3928% | 39 |
| 40 | — | VNET GROUP INC - NOTE 2.000%10/0 | $46.8M | 0.3% | +0% | — |
| 41 |  $AVTX | Avalo Therapeutics, Inc. | $46.2M | 0.3% | +173% | 11.7 |
| 42 |  $JOYY | JOYY Inc. | $46.1M | 0.3% | +21% | — |
| 43 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $44.1M | 0.3% | +31% | 41.5 |
| 44 |  $ENTA | ENANTA PHARMACEUTICALS INC | $35.3M | 0.2% | -16% | 17.8 |
| 45 |  $MAZE | Maze Therapeutics, Inc. | $33.1M | 0.2% | +197% | 10.3 |
| 46 |  $CGONCALL | CG Oncology, Inc. | $28.4M | — | +100% | 27 |
| 47 |  $MRK | Merck & Co., Inc. | $25.6M | 0.1% | -45% | 59.9 |
| 48 |  $WRBY | Warby Parker Inc. | $25.1M | 0.1% | NEW | 54.3 |
| 49 |  $FRNM | Freenome, Inc. | $24.5M | 0.1% | +0% | — |
| 50 |  $KLRA | Kailera Therapeutics, Inc. | $24.2M | 0.1% | NEW | — |
| 51 |  $RIO | RIO TINTO PLC | $17.4M | 0.1% | +241% | — |
| 52 |  $AXTA | Axalta Coating Systems Ltd. | $16.4M | 0.1% | NEW | — |
| 53 |  $ABVX | Abivax S.A. | $16.3M | 0.1% | +6000% | — |
| 54 |  $VNET | VNET Group, Inc. | $16.0M | 0.1% | +220% | — |
| 55 |  $NTES | NetEase, Inc. | $15.8M | 0.1% | -58% | — |
| 56 |  $BIIB | BIOGEN INC. | $15.3M | 0.1% | NEW | 64.7 |
| 57 |  $TSHA | Taysha Gene Therapies, Inc. | $15.3M | 0.1% | NEW | 4.9 |
| 58 |  $MOBI | Mobia Medical, Inc. | $15.1M | 0.1% | NEW | — |
| 59 | $MSTR | Strategy Inc | $14.2M | 0.1% | NEW | 17.9 |
| 60 |  $NERV | Minerva Neurosciences, Inc. | $13.1M | 0.1% | +0% | — |
| 61 |  $ALMR | Alamar Biosciences, Inc. | $12.5M | 0.1% | NEW | — |
| 62 |  $ALVO | Alvotech | $10.6M | 0.1% | +1332% | — |
| 63 |  $BBNX | Beta Bionics, Inc. | $9.3M | 0.1% | -84% | 29.8 |
| 64 |  $IFRX | InflaRx N.V. | $7.4M | 0.0% | NEW | — |
| 65 |  $SMG | SCOTTS MIRACLE-GRO CO | $6.0M | 0.0% | NEW | 45.8 |
| 66 |  $WAY | Waystar Holding Corp. | $5.4M | 0.0% | NEW | 65.5 |
| 67 |  $BC | BRUNSWICK CORP | $5.1M | 0.0% | NEW | 45.7 |
| 68 |  $GNTX | GENTEX CORP | $5.0M | 0.0% | NEW | 64.7 |
| 69 |  $IDXX | IDEXX LABORATORIES INC /DE | $4.7M | 0.0% | NEW | 73.8 |
| 70 |  $PRME | Prime Medicine, Inc. | $4.6M | 0.0% | +0% | 30.7 |
| 71 |  $CMC | COMMERCIAL METALS Co | $4.2M | 0.0% | NEW | 57.2 |
| 72 |  $JATT | JATT II Acquisition Corp. | $3.4M | 0.0% | NEW | — |
| 73 |  $SGMT | Sagimet Biosciences Inc. | $3.2M | 0.0% | NEW | — |
| 74 | — | STRATEGY INC - NOTE 3/0 | $2.3M | 0.0% | NEW | — |
| 75 |  $SMC | Summit Midstream Corp | $1.7M | 0.0% | +0% | 51 |
| 76 |  $TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $1.4M | 0.0% | -89% | — |
| 77 | $RVMD | Revolution Medicines, Inc. | $1.1M | 0.0% | +0% | — |
| 78 |  $COGT | Cogent Biosciences, Inc. | $657,900 | 0.0% | +0% | — |
| 79 |  $ANNA | AleAnna, Inc. | $297,000 | 0.0% | +0% | 70 |
| 80 | $ANNA | AleAnna, Inc. | $227,360 | 0.0% | +0% | 70 |
| 81 |  $WELL | WELLTOWER INC. | $226,970 | 0.0% | -100% | 59.8 |
| 82 | — | SOLID POWER INC - *W EXP 12/08/202 | $41,423 | 0.0% | +0% | — |
| 83 |  $BGL | Blue Gold Ltd | $30,696 | 0.0% | -15% | — |
| 84 |  $PACB | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | $23,856 | 0.0% | -89% | 17.1 |
| 85 |  $GERN | GERON CORP | $18,432 | 0.0% | -67% | — |
| 86 |  $NVNI | Nvni Group Ltd | $17,550 | 0.0% | +0% | — |
| 87 |  $CGC | Canopy Growth Corp | $17,100 | 0.0% | -40% | 26 |
| 88 |  $RANI | Rani Therapeutics Holdings, Inc. | $15,740 | 0.0% | -73% | — |
| 89 |  $BYND | BEYOND MEAT, INC. | $14,250 | 0.0% | +0% | 38.4 |
New Positions (21)
$EA ELECTRONIC ARTS INC.$1.6B$PBLS Parabilis Medicines, Inc.$64.8M$NVS NOVARTIS AG$56.9M$WRBY Warby Parker Inc.$25.1M$KLRA Kailera Therapeutics, Inc.$24.2M$AXTA Axalta Coating Systems Ltd.$16.4M$BIIB BIOGEN INC.$15.3M$TSHA Taysha Gene Therapies, Inc.$15.3M$MOBI Mobia Medical, Inc.$15.1M$ALMR Alamar Biosciences, Inc.$12.5M$IFRX InflaRx N.V.$7.4M$SMG SCOTTS MIRACLE-GRO CO$6.0M$WAY Waystar Holding Corp.$5.4M$BC BRUNSWICK CORP$5.1MExited Positions (105)
$SCHW SCHWAB CHARLES CORP
$GOOG Alphabet Inc.
$V VISA INC.
$DIS Walt Disney Co
$MA Mastercard Inc
$MCK MCKESSON CORP
$CNTA Centessa Pharmaceuticals plc
$TYRA Tyra Biosciences, Inc.
$THC TENET HEALTHCARE CORP
$CAH CARDINAL HEALTH INC
$PCVX Vaxcyte, Inc.
$DNTH Dianthus Therapeutics, Inc. /DE/$CGON CG Oncology, Inc.
$BITW Bitwise 10 Crypto Index ETFBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for FARALLON CAPITAL MANAGEMENT LLC including:
Track FARALLON CAPITAL MANAGEMENT LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for FARALLON CAPITAL MANAGEMENT LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: FARALLON CAPITAL MANAGEMENT LLC
13F Pro is an AI hedge fund tracker and stock research platform. For FARALLON CAPITAL MANAGEMENT LLC (SEC CIK: 909661), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in FARALLON CAPITAL MANAGEMENT LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.